Transcript Update on activities of the UNDCP in drug epidemiology

EMCDDA Meeting on Treatment Demand
Lisbon 2 October, 2002
Global Mechanisms
for Reporting of
Treatment Data
Juana M. Tomás Rosselló
Demand Reduction Section
UNDCP
Guiding Principles of the UNDCP
Data Collection Strategy
• Sensitivity to different information resources
• Based on agreed standards of good practice
• Comparability with other information sets
UNDCP’s Drug Demand Data
•
Instrument
ARQ (II/1)
D.R. questionnaire
Data collected
Annually
Biennially
Indicator data
Structures
Prevalence / problems
Contents
Trend reports
Contextual information
Methods of working
Target population
Coverage
Annual Reports Questionnaire (ARQ)
• To review the progress made in meeting the challenges
set out in the Political Declaration adopted by the
General Assembly
• To monitor and increase global understanding of the
extent and nature of drug abuse
Annual Reports Questionnaire (ARQ)
Part II: Drug Abuse
• Quantitative estimates and expert opinions on:
• prevalence of drug abuse among general and youth population
• IDU
• new developments in prevalence and patterns of drug abuse
• drug related morbidity (HIV, HBV, HCV) and mortality
• drug treatment attendance
• data collection capacity
Annual Reports Questionnaire (ARQ)
• Annually distributed to all Member States
• Global response rate ranged between 40% and 60%
• Revised format currently in use for the first time
• Electronic completion and submission made possible
• Submissions for 2001 received following new format,
improved responses both in quantity and quality
Percentage of countries submitting the ARQ
part II 2001, by region (n=105)
100
80
80
61
66
60
%
40
38
20
7
0
Africa
Americas
Asia
Europe
Oceania
Biennial Reports Questionnaire (BRQ)
• Mandated follow-up instrument of the UNGASS process
• To enable Member States to report on the progress
achieved in meeting the UNGASS objectives for 2003/08
• To monitor structures, methods of working, target
population, extent and coverage of programmes,
difficulties encountered
Biennial Reports Questionnaire (BRQ)
• Biennially distributed to all Member States
• Baseline reporting cycle 1998-2000 (n=109)
• Electronic completion and submission made possible
• Submissions covering the 2nd reporting cycle
received, similar number of countries responding
Percentage of countries submitting the BRQ in the
2nd reporting cycle (2000-2002), by region (n=116)
100
73
80
%
60
77
63
45
40
29
20
0
Africa
Americas
Asia
Europe
Oceania
BRQ 1998-2000: TREATMENT PROVISION
(% of countries out of 109reporting extensive provision, by
setting)
100
80
60
40
20
0
Hospitals
Detoxification
Primary care
Substitution
Prisons
Specialized
inpatient
Specialized
ambulatory
Non-pharmacological
Source: Consolidated first biennial report of the executive director on the implementation of the
outcome of the twentieth special session of the General Assembly. (E/CN.7/2001/16)
BRQ 1998-2000: INTERVENTIONS TO REDUCE
THE CONSEQUENCES OF DRUG ABUSE
(% of countries out of 109 reporting extensive and isolated
services)
60
40
20
di
st
ri
bu
tio
n
)
IV
(H
C
on
do
m
m
es
pr
og
ra
m
Te
st
in
g
of
c
lea
n
in
g
ag
en
ts
ex
ch
an
ge
Pr
ov
isi
on
N
ee
dl
e
at
io
n
in
fo
rm
Sa
fe
ty
pr
ev
en
tio
n
ve
rd
os
e
Em
Extensive
O
er
ge
nc
y
sh
elt
er
s
ut
re
ac
h
O
Lo
w
th
re
sh
ol
d
0
Isolated
Source: Consolidated first biennial report of the executive director on the implementation of the
outcome of the twentieth special session of the General Assembly. (E/CN.7/2001/16)
E/NR/2001/2
Drug treatment
SUMMARY EXPERT OPINIONS
Q48
Have people
received
treatment for
drug problems
in the past
year?
NO
YES
Q49
How are drugs
ranked in order
of the primary
cause of
receiving
treatment?
Put in numerical order
Q50
What has been the trend over
the past year in the numbers of
people receiving treatment?
Large Some Nogreat Some Large
increase increase change decrease decrease
Any drugs (type unspecified)
Ranking of drugs as
primary cause of
treatment:
Start with 1 for the
drug most frequently
the primary cause of
treatment, 2 for the
second most
frequent primary
cause, etc. If
necessary, you may
assign equal rank
numbers to more
than one drug.
Cannabis type
Heroin
Other opioids
Cocaine type
Amphetamine
Methamphetamine
Ecstasy'type
Otherdrugs
Drug treatment
QUANTITATIVE ESTIMATES
Q51
Do you have an estimate of the number
of people receiving treatment for drug
problems?
Q52
For which year does the estimate apply?
Which part of the country or selection of treatment
facilities is covered by the estimate?
Tick ONLY ON F
No  Proceed to Q59
Year of the national estimate
Yes
an estimate for the country as a whole
Year of the partial estimate
Yes
an estimate for a part of the country or
a selection of treatment facilities
Part of the country for which the estimate applies
Types of treatment facilities included and/or excluded
in the estimate
18
E/NR/2001/2
Drug treatment
Please complete
questions Q53-Q58
for the estimate
specified in Q52
QUANTITATIVE ESTIMATES
Q53
Q54
What is the
What is the
estimated
PERCENTAGE
estimated
NUMBER
of people
receiving
treatment
for drug
problems?
of people
receiving
treatment for
the FIRST
TIME EVER
among people
in treatment?
Q55
What is the
estimated
PERCENTAGE
of FEMALES
among people
in treatment
Q56
Q57
What is the
estimated
MEAN AGE
of people in
treatment?
What is the
estimated
PERCENTAGE
of DRUG
INJECTORS
among people
in treatment?
Any drugs (type unspecified)
Cannabis type
Heroin
Other opioids
Cocaine type
Amphetamine
Methamphetamine
Ecstasy'type
Other drugs
Q58
Which definition of 'people treated for drug problems'
applies to the figures in the columns of Q53-Q57 above?
Q53
Q54
Q55
Q56
Q57
Tick as
Appropriate
Tick as
Appropriate
Tick as
Appropriate
Tick as
Appropriate
Tick as
Appropriate
All people receiving treatment
during the year
People STARTING treatment
during the year
People in treatment at CENSUS
DATE in the year
People discharged from
treatment during the year
Other
If estimates for 'all drugs' in Q53-Q57 above include also treatment for alcohol problems,
please tick here 
19
E/NR/2001/2
20
Data collection capacity
Registers
Q59
Q60
Has your country
capacity with
regard to data
collection
instruments
specified below?
How would you qualify
the present suitability
of these instruments
for making national
estimates about the
drug situation?
NO
Poor
YES
Moderate Good
Specialised treatment register
Registers on drug-related morbidity
Registers on drug-related mortality
Survey instruments
Prevalence surveys among the general
population
Prevalence surveys among school
populations
Surveys among drug users
Qualitative research instruments
Rapid Situation Assessment
Other
Q61
If applicable, what are the main obstacles for implementation or improvement of data
collection instruments suitable for making national estimates about the drug situation?
2. Interventions focused on treatment and rehabilitation
119.
Please indicate which types of the following treatment and
rehabilitation programmes have been implemented or are ongoing and
how well the programmes have covered the target group in the settings
in which implementation has occurred. Also indicate whether the
specific programmes are gender-sensitive and whether they have been
evaluated.
(a)
DETOXIFICATION
If the type of intervention is not available, please leave blank and move on to the next item below.
Availability
(implemented/
ongoing)
If available, please indicate the level of
coverage of the target group
(only one answer)
Low
Medium
High




Correctional
institutions




Community
institutions




Specialised
addiction
treatment
(residential)




Specialised
addiction
treatment
(non-residential)




Social services




Other
(please specify)
_____________
_____________




General and
psychiatric
hospitals

Primary care and
other health
facilities



If available, please indicate the extent of
programme execution.
Gender-sensitive
Results evaluated
(b)
SUBSTITUTION TREATMENT (THERAPY), EXCLUDING
SHORT-TERM DETOXIFICATION
If the type of intervention is not available, please leave blank and move on to the next item below.
Availability
(implemented/
ongoing)
If available, please indicate the level of
coverage of the target group
(only one answer)
Low
Medium
High




Correctional
institutions




Community
institutions




Specialised
addiction
treatment
(residential)




Specialised
addiction
treatment
(non-residential)




Social services




Other
(please specify)
_____________
_____________




General and
psychiatric
hospitals

Primary care and
other health
facilities



If available, please indicate the extent of
programme execution.
Gender-sensitive
Results evaluated
(c)
NON-PHARMACOLOGICAL TREATMENT
If the type of intervention is not available, please leave blank and move on to the next item below.
Availability
(implemented/
ongoing)
If available, please indicate the level of
coverage of the target group
(only one answer)
Low
Medium
High




Correctional
institutions




Community
institutions




Specialised
addiction
treatment
(residential)




Specialised
addiction
treatment
(non-residential)




Social services




Other
(please specify)
_____________
_____________




General and
psychiatric
hospitals

Primary care and
other health
facilities



If available, please indicate the extent of
programme execution.
Gender-sensitive
Results evaluated
(d)
SOCIAL REINTEGRATION
If the type of intervention is not available, please leave blank and move on to the next item below.
Availability
(implemented/
ongoing)
If available, please indicate the level of
coverage of the target group
(only one answer)
Low
Medium
High




Correctional
institutions




Community
institutions




Specialised
addiction
treatment
(residential)




Specialised
addiction
treatment
(non-residential)




Social services




Other
(please specify)
_____________
_____________




General and
psychiatric
hospitals

Primary care and
other health
facilities



If available, please indicate the extent of
programme execution.
Gender-sensitive
Results evaluated
(e) OTHER APPROACHES (PLEASE SPECIFY):
_________________________________________________________
______
If the type of intervention is not available, please leave blank and move on to the next item below.
Availability
(implemented/
ongoing)
If available, please indicate the level of
coverage of the target group
(only one answer)
Low
Medium
High




Correctional
institutions




Community
institutions




Specialised
addiction
treatment
(residential)




Specialised
addiction
treatment
(non-residential)




Social services




Other
(please specify)
_____________
_____________




General and
psychiatric
hospitals

Primary care and
other health
facilities



If available, please indicate the extent of
programme execution.
Gender-sensitive
Results evaluated
120.
Please indicate if any of the following areas are causing difficulties
for your country in its interventions for the purpose of treatment and
rehabilitation pursuant to the Action Plan:
Existing national legislation
Financial constraints
Coordination and multisectoral cooperation
Technical expertise
Lack of appropriate systems and structures
Other
(please
_________________________________________
specify):